Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/9218/Sevindik-Omur-2019.pdf.jpg?sequence=3&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2019Author
Sevindik, Ömür GökmenGemici, Aliihsan
Usta, Furkan Selim
Çakır, Aslı
Sadri, Sevil
Bekoz, Hüseyin
Sargın, Fatma Deniz
Metadata
Show full item recordCitation
Sevindik, Ö. G., Gemici, A., Usta, F. S., Çakır, A., Sadri, S., Bekoz, H. ... Sargın, F. D. (2019). Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO). 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). Orlando Florida, December 7-10, 2019. https://dx.doi.org/10.1182/blood-2019-126195Abstract
Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. Despite growing evidence regarding its efficacy and safety among AML patients there is limited data about the use of GO in isolated extra-medullary relapsed AML. Extramedullary AML remains as an unmet clinical need regarding the poor prognosis and lack of a standard therapeutic approach. Our cases demonstrated a rapid and long lasting response with a favorable toxicity profile, in patients who were treated with GO as a single agent after an isolated extramedullary relapsing disease.
Source
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)Volume
134Issue
Supplement:1Collections
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6677]